The muscle protein titin has long been the titan of the molecular world. Built of more than 34,000 amino acids and weighing in at a hefty 3.7 megadaltons, titin has long been considered the largest protein in the world—until now.

Actinogen Medical’s cortisol blocker has missed the primary endpoint of a phase 2 study in depression, leaving the Australian biotech to focus on its potential in Alzheimer’s disease.

Actinogen Medical’s cortisol blocker has missed the primary endpoint of a phase 2 study in depression, leaving the Australian biotech to focus on its potential in Alzheimer’s disease.

Avidity Biosciences impressed investors with phase 1/2 data in Duchenne muscular dystrophy (DMD) Friday, extending its winning streak in the clinic. But closer examinations of the data revealed details that analysts said present a much more nuanced picture than implied by the headline result.

Antibody-drug conjugates (ADCs) have been at the center of many a billion-dollar biobuck licensing deal over the last year, but Bivictrix Therapeutics feels like it’s been missing out.

Nearly a year after it announced a collaboration with Microsoft, digital pathology player Paige unveiled the second generation of an image-based artificial intelligence model to help detect cancer.

CEO David Ricks can see the companies setting up tents at basecamp behind Eli Lilly in an attempt to get a foothold of the obesity market. But Lilly’s already been to the summit and is coming back down for another trip.

The confetti is still flying from Eli Lilly’s party celebrating the approval of Alzheimer’s disease therapy donanemab, but the company is yet again facing the harsh reality of the neurodegenerative disease with the failure of an early tau-targeting med.

After an FDA rejection last year, Aldeyra Therapeutics has scored a clinical win for dry eye drug reproxalap, which significantly reduced ocular discomfort in a new phase 3 study.

Aminoglycosides are cheap and effective antibiotics that can come with a heavy price—hearing loss. Commonly used in developing countries and for infants in neonatal intensive care, just a few days of treatment can cause these powerful drugs to build up in the inner ear and kill the sensory hair cells that enable hearing, resulting in irreversible damage.